Stock Track | Genmab A/S Soars 5.03% on Strong Q4 Earnings and Analyst Upgrade

Stock Track

Feb 13, 2025

Genmab A/S (NASDAQ: GMAB) shares surged 5.03% in the pre-market session on Thursday, driven by a combination of solid fourth-quarter financial results and an analyst rating upgrade.

The Danish biotechnology company reported impressive financial performance for the fourth quarter and full year 2024. Highlights include a 31% increase in total revenue growth, a 26% rise in operating profit, and nearly $3 billion in cash position at year-end. The strong results were fueled by the success of Genmab's eight commercialized medicines, including EPKINLY and Tivdak, which generated sales of $281 million and $131 million, respectively, in 2024.

Additionally, Genmab's strategic acquisition of ProfoundBio for $1.8 billion and the integration of Rina-S into its pipeline have been successful, with plans for two Phase III trials underway. The company also returned capital to shareholders through a $500 million share buyback program in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197613144"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197613144\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197613144?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 23:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197613144","market":"us","top_or_hot":-1,"title":"Stock Track | Genmab A/S Soars 5.03% on Strong Q4 Earnings and Analyst Upgrade","media":"Stock Track","content":"<p>Genmab A/S (NASDAQ: GMAB) shares surged 5.03% in the pre-market session on Thursday, driven by a combination of solid fourth-quarter financial results and an analyst rating upgrade.</p>\n\n<p>The Danish biotechnology company reported impressive financial performance for the fourth quarter and full year 2024. Highlights include a 31% increase in total revenue growth, a 26% rise in operating profit, and nearly $3 billion in cash position at year-end. The strong results were fueled by the success of Genmab's eight commercialized medicines, including EPKINLY and Tivdak, which generated sales of $281 million and $131 million, respectively, in 2024.</p>\n\n<p>Additionally, Genmab's strategic acquisition of ProfoundBio for $1.8 billion and the integration of Rina-S into its pipeline have been successful, with plans for two Phase III trials underway. The company also returned capital to shareholders through a $500 million share buyback program in 2024.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Genmab A/S Soars 5.03% on Strong Q4 Earnings and Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Genmab A/S Soars 5.03% on Strong Q4 Earnings and Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 23:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genmab A/S (NASDAQ: GMAB) shares surged 5.03% in the pre-market session on Thursday, driven by a combination of solid fourth-quarter financial results and an analyst rating upgrade.</p>\n\n<p>The Danish biotechnology company reported impressive financial performance for the fourth quarter and full year 2024. Highlights include a 31% increase in total revenue growth, a 26% rise in operating profit, and nearly $3 billion in cash position at year-end. The strong results were fueled by the success of Genmab's eight commercialized medicines, including EPKINLY and Tivdak, which generated sales of $281 million and $131 million, respectively, in 2024.</p>\n\n<p>Additionally, Genmab's strategic acquisition of ProfoundBio for $1.8 billion and the integration of Rina-S into its pipeline have been successful, with plans for two Phase III trials underway. The company also returned capital to shareholders through a $500 million share buyback program in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GMAB","symbol_name":"Genmab A/S","start_time":0,"source_url":"","article_id":"1197613144","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197613144","pubTimestamp":1739461730,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Genmab A/S  shares surged 5.03% in the pre-market session on Thursday, driven by a combination of solid fourth-quarter financial results and an analyst rating upgrade.The Danish biotechnology company reported impressive financial performance for the fourth quarter and full year 2024. Highlights include a 31% increase in total revenue growth, a 26% rise in operating profit, and nearly $3 billion in cash position at year-end. The strong results were fueled by the success of Genmab's eight commerci","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GMAB":"Genmab A/S"},"translate_title":"股票跟踪Genmab A/S因强劲的第四季度盈利和分析师升级而飙升5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":1},"content_text":"Genmab A/S (NASDAQ: GMAB) shares surged 5.03% in the pre-market session on Thursday, driven by a combination of solid fourth-quarter financial results and an analyst rating upgrade.\nThe Danish biotechnology company reported impressive financial performance for the fourth quarter and full year 2024. Highlights include a 31% increase in total revenue growth, a 26% rise in operating profit, and nearly $3 billion in cash position at year-end. The strong results were fueled by the success of Genmab's eight commercialized medicines, including EPKINLY and Tivdak, which generated sales of $281 million and $131 million, respectively, in 2024.\nAdditionally, Genmab's strategic acquisition of ProfoundBio for $1.8 billion and the integration of Rina-S into its pipeline have been successful, with plans for two Phase III trials underway. The company also returned capital to shareholders through a $500 million share buyback program in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}